Lupin Q2 results: Net profit jumps 74% to Rs 853 crore, revenue up 13%

Lupin's EBITDA came in at Rs 1,340.3 crore, up 46 percent from Rs 917.7 crore

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Mumbai-based pharma company Lupin Ltd reported a 74.1 percent year-on-year surge in consolidated net profit at Rs 852.63 crore for the July-September quarter of FY25, aided by higher sales.

The company had reported a profit of Rs 489.67 crore in the same period last year.

Revenue came in at Rs 5,672.73 crore, up 12.6 percent from the year-ago quarter of Rs 5,038.56 crore.

North America Q2 sales were Rs 1,971.1 crore, up 5.6 percent compared to Rs 1,866.6 crore, accounting for 36 percent of Lupin’s global sales. India formulation sales for stood at Rs 2,009.6 crore, up 18.8 percent compared to Rs 1,691.5 crore year ago, accounting for 37 percent of global sales.

The company's earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 1,382.7 crore, up 44.3 percent from Rs 958.2 crore year ago. The EBITDA margin came in at 25.2 percent, as against 19.4 percent in the year-ago period.

During the quarter, Lupin received approval for 10 ANDA from the US, taking its cumulative ANDA filings with the US FDA to 431 as of September 30, 2024, with the company having received 329 approvals to date.

“The second quarter of FY25 reflects continued strength in our business across regions. With 40 percent of our US revenues now coming from complex generics, India back to double-digit growth and our pipeline delivering consistently, we aim to continue improving our performance aided by sustained operating efficiencies and investment in technology," said Nilesh Gupta, managing director.

Lupin is an integrated pharmaceutical company with a presence across research, manufacturing and marketing of formulations and APIs. It is the third largest pharmaceutical player in the US by prescriptions and the seventh largest in IPM, according to IQVIA data.